• In recent months, analysts at major banks including Citigroup and UBS have reiterated positive ratings on Olema Pharmaceuticals, citing confidence in its clinical-stage pipeline and strengthened balance sheet following a roughly US$218.5 million public offering in November 2025.
• An interesting angle for investors is Olema’s inclusion on Citigroup’s 90-day catalyst watchlist, highlighting expectations around upcoming clinical and corporate milestones.
• Next, we’ll examine how Olema’s addition to a major analyst’s 90-day catalyst watch shapes the company’s broader investment narrative.

These 16 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

What Is Olema Pharmaceuticals' Investment Narrative?

For someone considering Olema, the core belief is that its clinical programs, especially palazestrant and early‑stage assets like OP‑3136, can eventually justify today’s loss‑making, zero‑revenue profile. The recent Citigroup and UBS calls, plus Olema’s inclusion on Citi’s 90‑day catalyst watch, sharpen attention on near‑term data readouts, trial progress and any updates around partnering or commercialization plans, which now feel more central to the story than before. The strengthened balance sheet after the roughly US$218.5 million raise reduces immediate funding pressure, but it does not remove the key risks: clinical trial setbacks, ongoing cash burn, a still‑new management team and a valuation that already prices in meaningful future success. In that context, the news looks material mainly because it concentrates market expectations into the next few months.

However, investors should be aware of how quickly sentiment could reverse if catalysts disappoint. Olema Pharmaceuticals' shares have been on the rise but are still potentially undervalued by 16%. Find out what it's worth.

Exploring Other Perspectives

Three fair value estimates from the Simply Wall St Community range from about US$4.53 to US$45.30, underscoring how differently people are sizing Olema’s upside against its very real clinical and funding risks. This spread sits alongside heightened focus on Citi’s 90‑day catalyst watch, inviting you to weigh multiple viewpoints before deciding how those near term events might reshape the company’s longer term potential.

Explore 3 other fair value estimates on Olema Pharmaceuticals - why the stock might be worth as much as 77% more than the current price!

Build Your Own Olema Pharmaceuticals Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Olema Pharmaceuticals research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Olema Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Olema Pharmaceuticals' overall financial health at a glance.

Searching For A Fresh Perspective?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Outshine the giants: these 28 early-stage AI stocks could fund your retirement.
• Rare earth metals are the new gold rush. Find out which 39 stocks are leading the charge.
• This technology could replace computers: discover 29 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.